Presenter: Dr. Sherly Mosessian earned her bachelors degree in Biochemistry, followed by her Ph.D from UCLA Department of Molecular, Medical Pharmacology, with publications in tumor signaling, molecular imaging targets and clinical trials of Position Emission Tomography (PET) probes. In her role as the Chief Scientific Officer of SOFIE she formulates the strategic plan for scientific objectives of the organization, including leading the FAPI clinical development program.
Date: June 14, 2023
Time: 3:30pm – 4:30pm EDT
Who should attend? PET Interpreters, Technologists, Referring Physicians, Marketers
In this session, Dr. Mosessian will:
- explain the significance of FAP as a target in oncology
- highlight the progress made to date with FAP targeting ligands for diagnostic use in oncology
- describe the current clinical trials and regulatory landscape for FAP targeting ligands
THIS ACTIVITY IS APPROVED FOR CREDIT BY THE SNMMI